Atlas Trials

A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients

Clinical trial NCT05758610 · UNKNOWN

Trial details

NCT number
NCT05758610
Sponsor
Shengke Pharmaceuticals (Jiangsu) Limited, China
Status
UNKNOWN
Phase
Phase 1
Study type
INTERVENTIONAL
NHL, AdultAML, Adult Recurrent
Start date
2022-11-04
Primary completion
2025-12-01
Enrollment
60

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.